
Shares of life sciences firm Bio-Rad Laboratories BIO.N plunge 15.3% to $247.75 premarket
Co on Wednesday reported Q4 adjusted profit per share of $2.51, below LSEG-compiled analysts' average estimate of $2.70
However, revenue of $693.2 million beat analysts' average expectation of $688.76 million
Quarterly sales in the life-science segment fell 2.6% year-on-year to $267.9 million, due to constrained academic research and biotech funding
Up to last close, stock was down 3.5% YTD